Sigumir is a peptide bioregulator made from cartilage tissue, and it’s studied for its support of cartilage cells, collagen synthesis, and bone mineral density. Cartilage is one of the slowest tissues in the body to renew itself, which is exactly why the peptide signals that direct it matter so much.
There’s a finding buried in the cartilage peptide literature that most product pages never mention. When researchers tested a cartilage tissue complex head to head against a synthetic peptide for bone protection, the tissue complex won.
Key Takeaways
The Short Version
Sigumir is a cartilage peptide bioregulator studied for its support of cartilage cell function, collagen production, and bone mineral density.
In aging rats, a cartilage tissue preparation both prevented loss of bone mineral density and increased density that had already fallen.
The related AED peptide has been shown to increase collagen I, sirtuin-1, and sirtuin-6 synthesis in human cells during replicative aging.
Evidence is animal and cell-based, so treat Sigumir as long-game structural support rather than a joint painkiller.
What Sigumir Is
Sigumir is a short-chain peptide complex extracted from the cartilage tissue of young animals. It’s designated A-4 in the Khavinson bioregulator catalogue, a family of tissue-specific peptide complexes developed over three decades at the St. Petersburg Institute of Bioregulation and Gerontology.
BioLongevity sells it as BioCartilage (A-4).
Every tissue makes its own regulatory peptides. As we age, those signals decline. A bioregulator reintroduces peptides sourced from the matching tissue.
New to the category? Read what peptide bioregulators are first.
How Cartilage Peptides Work
Short peptides act inside the cell, not on receptors at its surface.
They cross the cell membrane using standard peptide transporters. The POT family (PEPT1, PEPT2) and LAT carriers are described in a 2022 review as the likely route for ultrashort peptides. Once inside, they can reach DNA and influence which genes get transcribed.
For cartilage, three mechanisms are doing the work.
| Mechanism | What the research shows |
|---|---|
| Collagen synthesis | The AED peptide increased collagen I production in human cells during aging |
| Sirtuin activation | AED raised sirtuin-1 and sirtuin-6, both tied to cellular repair |
| Stem cell direction | Peptides can steer stem cells toward becoming cartilage cells |
That third one is where the science is heading. A 2023 review from the Khavinson group mapped how peptides regulate chondrogenic differentiation, the process by which mesenchymal stem cells become chondrocytes. Chondrocytes are the cells that build and maintain cartilage. The review frames directed stem cell differentiation as one of the more promising routes to supporting joint tissue.
Tissue specificity holds here too. When polypeptides from seven tissues were applied to matching organotypic cultures from young and old rats, each stimulated only its own tissue, raising the proliferation marker PCNA and lowering p53. Cartilage peptides acted on cartilage.
What the Research Says About Sigumir Peptide Benefits
Bone mineral density
This is the strongest and most specific result in the cartilage peptide literature.
Researchers used an ovariectomy model in rats, a standard way to model the bone loss that follows menopause, and compared two treatments: a preparation based on cartilage tissue extract, and a synthetic peptide called T-31.
Both showed an osteoprotective effect. The cartilage tissue preparation was significantly more effective.
And it worked in both directions. It prevented the drop in bone mineral density after ovariectomy, and it raised density that had already fallen.
That’s a preventive effect and a corrective one, from the same tissue complex Sigumir is built on. In animals, with a female bone-loss model. Worth stating clearly. But it’s the kind of result that explains why cartilage bioregulators keep showing up in longevity protocols.
Collagen and cellular repair
The AED peptide (Ala-Glu-Asp) is the short peptide most associated with cartilage tissue in this research line.
In human cells undergoing replicative aging, AED activated the synthesis of sirtuin-1, sirtuin-6, and collagen I. Sirtuins are the repair enzymes at the center of most longevity research. Collagen I is a primary structural protein in connective tissue.
A peptide that lifts both, in aging cells, is doing exactly what you’d want a structural bioregulator to do.
Cellular aging markers
Short peptides in this family also push back on senescence directly. In human stem cells cultured through long-term expansion, AEDG and KED peptides reduced expression of the senescence markers p16 and p21 by roughly 1.5 to 3.2 times compared with untreated cells.
And in a study of gene expression during stem cell aging, AED, KED, and KE peptides enhanced IGF1 gene expression by 3.5 to 5.6 times. IGF1 is a central growth and tissue-maintenance signal.
The honest evidence tier
There is no published human clinical trial on Sigumir. The evidence is animal and cell-based.
What it adds up to is a coherent mechanistic story with a strong preclinical bone density result behind it. Human confirmation is the next step, not a completed one. Treat Sigumir as structural support for the long game.
Who Sigumir Is For
- Adults over 40 who want to support joint and bone tissue before density and cartilage volume start declining.
- Athletes and lifters putting sustained mechanical load through joints and connective tissue.
- Women approaching or past menopause, given that the bone density research used a postmenopausal model.
- Anyone building a systems-based longevity routine who wants a structural pillar alongside metabolic and cognitive support.
Joint pain that’s persistent, sharp, or swelling-related is a clinician’s question, not a supplement’s. Get it looked at.
Ask a qualified clinician before starting any supplement if you are pregnant, nursing, taking medication, or managing a medical condition.
What to Look for in a Cartilage Peptide Bioregulator
| What to check | Why it matters |
|---|---|
| Third-party testing | Confirms the peptide content matches the label |
| Certificate of Analysis | Batch-level proof of identity, purity, and contaminant screening |
| Named tissue source | Cartilage specificity is the mechanism, so the source belongs on the label |
| U.S. GMP manufacturing | Manufacturing standards you can trace |
| Transparent dose | No proprietary blend hiding the actual amount |
BioLongevity publishes a Certificate of Analysis for every batch. That document is the difference between a claim and a fact.
Frequently Asked Questions
Is Sigumir the same as collagen?
No. Collagen supplements supply amino acid building blocks. Sigumir supplies short regulatory peptides that signal cartilage cells to build. Different mechanism, different job. Some people use both.
Does Sigumir help with joint pain?
Sigumir is studied for its support of cartilage cell function and structural tissue, not for pain relief. It isn’t an analgesic and shouldn’t be treated as one.
Is Sigumir the same as glucosamine or chondroitin?
No. Glucosamine and chondroitin are cartilage matrix components. Sigumir is a peptide bioregulator that acts on gene expression inside cartilage cells.
How long before Sigumir does anything?
Cartilage turns over slowly. This is a long-horizon supplement, and the research protocols behind it ran in cycles over months. Follow the product label unless your clinician recommends otherwise.
Can Sigumir be stacked with other bioregulators?
Yes. Tissue-specific peptides are commonly combined by system. See the full bioregulator collection.
Where to Start
Bone density and cartilage volume are two of the quietest losses in aging. Nothing hurts until something breaks, and by then the structural work should have started years earlier.
BioCartilage (A-4) is BioLongevity’s cartilage peptide bioregulator, formulated with the natural cartilage peptide complex, third-party tested, and manufactured in the U.S. under GMP standards. Every batch has a published Certificate of Analysis, so you can check the work before you commit to the routine.
Ask a qualified clinician before starting any supplement if you are pregnant, nursing, taking medication, or managing a medical condition.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Khavinson VK, Ryzhak GA, Mikhailova ON. Saint Petersburg Institute of Bioregulation and Gerontology: achievements and prospects. Advances in Gerontology. 2013;26(1):11-19. PubMed
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences. 2022;23(14):7733. DOI
- Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G. Peptide Regulation of Chondrogenic Stem Cell Differentiation. International Journal of Molecular Sciences. 2023;24(9):8415. DOI
- Ryzhak AP, Chalisova NI, Lin’kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. Polypeptides influence on tissue cell cultures regeneration of various age rats. Advances in Gerontology. 2015;28(1):97-103. PubMed
- Povorozniuk VV, Khavinson VK, Makogonchuk AV, Ryzhak GA, Kreslov EA, Gopkalova IV. Effect of peptide regulators on the structural and functional status of bone tissue in ageing rats. Advances in Gerontology. 2007;20(2):134-137. PubMed
- Fridman NV, Linkova NS, Kozhevnikova EO, Gutop EO, Khavinson VK. Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging. Bulletin of Experimental Biology and Medicine. 2020;170(1):154-157. DOI
- Sinjari B, Diomede F, Khavinson V, et al. Short Peptides Protect Oral Stem Cells from Ageing. Stem Cell Reviews and Reports. 2020;16(1):159-166. DOI
- Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanyushin B. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Molecular Biology Reports. 2020;47(6):4323-4329. DOI